| InVitria to Launch "BE FREE" Promotion at TERMIS ‘08 in San Diego Stem cell culture innovator asks the regenerative medicine community: "Are Your Cells Free?" Learn more about InVitria at TERMIS North America 2008, Dec. 7-10 in San Diego, CA. Fort Collins, CO. Stem cell culture researchers and the regenerative medicine community are meeting at the 2008 North American Tissue Engineering Meeting (www.termis.org/na2008/) in San Diego on Dec. 7-10. They will have the chance to learn how InVitria's product line can make their cells "Be Free" of animal components by using defined cell culture media supplements, while also receiving a complimentary InVitria "BE FREE" t-shirt. InVitria's Cellastim (www.Cellastim.com) a recombinant albumin is an animal free and defined cell culture media supplement. Cellastim has been shown to outperform animal derived albumins such as human serum albumin and bovine serum albumin. In addition, InVitria's Lacromin (www.Lacromin.com) a recombinant lactoferrin is an animal free growth factor that improves cell viability in long-term culture. "We are excited to attend this premier annual event for the tissue engineering community," said Brandy Sargent, InVitria's Sales Manager. "TERMIS is a great venue for InVitria to share its successes, while also learning from an exceptionally talented group of individuals the discoveries, applications and products for stem cell and regenerative medicine." "Stem cell media and regenerative medicine are exciting applications for the products we have developed," said Dr. Ning Huang, InVitria's VP of Research and Development. "There is an urgent need to eliminate risks of using animal components in these applications and that is a perfect fit for Cellastim and Lacromin." About InVitria (www.InVitria.com) To learn more about InVitria's products, please contact us by e-mail or phone. E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it Phone: 1-800-916-8311
|
-
Blog: The Cell Culture Dish
Strategies for Improving Viral Yield in Vaccine Manufacturing
A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More
-
Latest News
InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference
March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more
